We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amid Mylan’s EpiPen pricing firestorm in 2016 and 2017, the company came under fire for misclassifying the lifesaving injector as a generic on Medicaid, allowing it to drastically underpay rebates.